Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

PURPOSE: To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD). DESIGN: Multicenter, noninferiority factorial trial with equal allocation to groups. The noninferiority limit was 3.5 letters. This trial i...

Полное описание

Библиографические подробности
Главные авторы: Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B
Формат: Journal article
Язык:English
Опубликовано: 2012